Observational studyBlood advances2025
Severe parvovirus B19 infection in patients with sickle cell disease hospitalized in intensive care units.
Observational study in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characterization of near-complete hepatitis E virus genomes of genotype 1e and 4b detected from humans in Cameroon.Microbiology resource announcements · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractParvovirus B19 infection can lead to severe complications in patients with chronic hemolysis. The aim of this study was to describe severe parvovirus B19 infections in adult patients with sickle cell disease (SCD). In this multicenter, retrospective, observational cohort study, adult patients with SCD admitted to intensive care units (ICUs) between 2011 and 2024 with acute parvovirus B19 infection were included. Unsupervised analysis was performed including clinical and biological characteristics to identify clusters of patients with different outcomes. Clinical phenotypes were defined based on patient clustering. Parvovirus B19 genomes from ICU (n = 15) and non-ICU control patients (n = 15) admitted to the hospital during the same period were sequenced and compared. Sixty-one patients (52% female; median age, 29 years [interquartile range, 24-38]) from 8 ICUs in France were included. Three clusters of patients were identified. From these clusters, 3 groups of patients with distinct clinical phenotype were identified: erythroblastopenia (n = 26), bone marrow necrosis (BMN) and fat cerebral embolism syndrome (CFE; n = 17), and other vaso-occlusive manifestations (n = 18). Length of stay in the ICU and hospital was longer in patients with BMN/CFE. There was no difference in parvovirus B19 genotype or NS1 or VP1/2 amino acid diversity between the groups. Similar results were observed between patients who were admitted to the ICU and those who were not. ICU patients with SCD and acute parvovirus B19 infection presented 3 clinical phenotypes associated with different initial severity and outcome but with similar parvovirus B19 clades and amino acid diversity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.